TITLE

Operational research in malawi: making a difference with cotrimoxazole preventive therapy in patients with tuberculosis and HIV

PUB. DATE
January 2011
SOURCE
BMC Public Health;2011, Vol. 11 Issue 1, p593
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
The article informs on an operational research conducted in Malawi to determine the efficacy of cotrimoxazole in improving treatment outcomes of patients suffering from tuberculosis (TB) alongwith human immunodeficiency virus (HIV) infection and the impact of drug in reducing mortality. It is informed that district and family-based research was conducted between 1999 and 2005. Also, decrease in mortality and improvement in treatment outcome was observed in patients receiving cotrimoxazole.
ACCESSION #
65251572

 

Related Articles

  • In the News.  // Nature Reviews Microbiology;May2010, Vol. 8 Issue 5, p316 

    The article offers news briefs related to bacterial diseases in 2010. Studies have revealed that H1N1 influenza virus have structural similarities with haemagglutin proteins. Two researchers have developed a theoretical model to assess whether environmental and behavioral factors could affect...

  • Role of co-trimoxazole prophylaxis in reducing mortality in HIV infected adults being treated for tuberculosis: randomised clinical trial. Nunn, Andrew J.; Mwaba, Peter; Chintu, Chifumbe; Mwinga, Alwyn; Darbyshire, Janet H.; Zumla, Alimuddin // BMJ: British Medical Journal (International Edition);7/26/2008, Vol. 337 Issue 7663, p220 

    Objective To assess the impact of prophylactic oral.co- trimoxazole in reducing mortality in HIV positive Zambian adults being treated for pulmonary tuberculosis. Design Double blind placebo controlled randomised clinical trial. Participants Two groups of antiretroviral treatment naive adults...

  • Timing, rates, and causes of death in a large South African tuberculosis programme. Field, Nigel; Lim, Megan S. C.; Murray, Jill; Dowdeswell, Robert J.; Glynn, Judith R.; Sonnenberg, Pam // BMC Infectious Diseases;2014, Vol. 14 Issue 1, p1 

    Background: Tuberculosis (TB) mortality remains high across sub-Saharan Africa despite integration of TB and HIV/ART programmes. To inform programme design and service delivery, we estimated mortality by time from starting TB treatment. Methods: Routinely collected data on TB treatment, vital...

  • Reducing case fatality in HIV-infected TB patients in sub-Saharan Africa. Harries, A. D. // Southern African Journal of Epidemiology & Infection;2009, Vol. 24 Issue 3, p1 

    HIV-infected patients with tuberculosis (TB) have much higher case fatality rates compared with non-HIV-infected patients. There are various reasons for this high mortality that include delayed presentation and advanced TB at the time of diagnosis, incorrect diagnosis of smearnegative TB and...

  • Predictors of mortality among TB-HIV Co-infected patients being treated for tuberculosis in Northwest Ethiopia: a retrospective cohort study. Sileshi, Balewgizie; Deyessa, Negussie; Girma, Belaineh; Melese, Muluken; Suarez, Pedro // BMC Infectious Diseases;2013, Vol. 13 Issue 1, p1 

    Background: Tuberculosis (TB) is the leading cause of mortality in high HIV-prevalence populations. HIV is driving the TB epidemic in many countries, especially those in sub-Saharan Africa. The aim of this study was to assess predictors of mortality among TB-HIV co-infected patients being...

  • TB treatment outcomes among TB-HIV co-infections in Karnataka, India: how do these compare with non-HIV tuberculosis outcomes in the province? Suresh Shastri; Balaji Naik; Anita Shet; Bharat Rewari; De Costa, Ayesha // BMC Public Health;2013, Vol. 13 Issue 1, p1 

    Background: India accounts for 23% of the global incidence of TB cases; it also has an estimated 2.3 million HIV infections. Of the 2 million TB incident cases, 5% occurred in HIV infected persons. The country has large national TB and HIV control programs. This paper describes characteristics...

  • Pay attention to drug interactions to ensure successful treatment of tuberculosis and HIV co-infection.  // Drugs & Therapy Perspectives;Aug2007, Vol. 23 Issue 8, p16 

    The article discusses a variety of issues concerning the treatment regimen for tuberculosis (TB) and HIV co-infection. Drug interactions should be considered when developing a treatment regimen for a patient with TB and HIV comorbidity. According to the author, effective antitubercular and...

  • Active Tuberculosis in Individuals Infected with Human Immunodeficiency Virus after Isoniazid Prophylaxis. Fitzgerald, Daniel W.; Morse, Michelle Marie; Pape, Jean William; Johnson Jr., Warren D. // Clinical Infectious Diseases;12/1/2000, Vol. 31 Issue 6, p1495 

    Reports on a study which determined the timing and outcome of active tuberculosis in HIV-positive patients who had previously received isoniazid (INH) prophylaxis. Results of examination for acid-fast bacteria; Comparison of the length of INH prophylaxis regimen; Rationale for the cautious...

  • Treatment. Laine, Christine; Williams, Sankey; Sox, Harold C. // Annals of Internal Medicine;6/2/2009, Vol. 150 Issue 11, pITC6.9 

    The article focuses on the treatment of patients with latent tuberculosis. Latent tuberculosis is diagnosed when a person tests positive for tuberculosis, but there is no evidence of active disease. It is suggested that before starting treatment for latent tuberculosis, clinicians should...

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics